

# What reinfections mean for COVID-19

Lancet Infectious Diseases, The  
21, 3-5

DOI: [10.1016/s1473-3099\(20\)30783-0](https://doi.org/10.1016/s1473-3099(20)30783-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Coronavirus vaccine development: from SARS and MERS to COVID-19. <i>Journal of Biomedical Science</i> , 2020, 27, 104.	2.6	287
2	Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. <i>Clinical Microbiology and Infection</i> , 2021, 27, 315-318.	2.8	141
3	A case of SARS-CoV-2 reinfection in Ecuador. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e142.	4.6	72
4	Ct values and infectivity of SARS-CoV-2 on surfaces. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e141.	4.6	41
5	Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients. <i>Journal of Neurotrauma</i> , 2021, 38, 1-43.	1.7	68
6	Serological Evidence for Reinfection with SARS-CoV-2; An Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
7	A fractional complex network model for novel corona virus in China. <i>Advances in Difference Equations</i> , 2021, 2021, 5.	3.5	4
8	Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications. <i>Journal of Korean Medical Science</i> , 2021, 36, e59.	1.1	51
9	Immune determinants of COVID-19 disease presentation and severity. <i>Nature Medicine</i> , 2021, 27, 28-33.	15.2	490
11	Evidence for immunity to SARS-CoV-2 from epidemiological data series. <i>F1000Research</i> , 0, 10, 50.	0.8	0
12	Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 193-196.	1.8	34
14	Towards Bayesian Evaluation of Seroprevalence Studies. <i>Medical Sciences Forum</i> , 2021, 4, .	0.5	0
15	Clinical characteristics of re-hospitalized COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1245-1252.	1.3	8
16	Do Antibody Positive Healthcare Workers Have Lower SARS-CoV-2 Infection Rates than Antibody Negative Healthcare Workers? Large Multi-Centre Prospective Cohort Study (The SIREN Study), England: June to November 2020. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7
17	Herd immunity by infection is not an option. <i>Science</i> , 2021, 371, 230-231.	6.0	47
18	The 2020 race towards SARS-CoV-2 specific vaccines. <i>Theranostics</i> , 2021, 11, 1690-1702.	4.6	71
19	Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2. <i>The Cochrane Library</i> , 0, , .	1.5	4
20	Epidemiological characteristics, reinfection possibilities and vaccine development of SARS CoV2: A global review. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 1095.	0.3	3

#	ARTICLE	IF	CITATIONS
21	Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. <i>Heliyon</i> , 2021, 7, e05951.	1.4	15
22	SARS-CoV-2: vaccines in the pandemic era. <i>Military Medical Research</i> , 2021, 8, 1.	1.9	104
23	Looking beyond COVID-19 vaccine phase 3 trials. <i>Nature Medicine</i> , 2021, 27, 205-211.	15.2	473
24	Dynamics of a Dual SARS-CoV-2 Lineage Co-Infection on a Prolonged Viral Shedding COVID-19 Case: Insights into Clinical Severity and Disease Duration. <i>Microorganisms</i> , 2021, 9, 300.	1.6	48
25	Comparison of nasopharyngeal samples for SARS-CoV-2 detection in a paediatric cohort. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 1078-1081.	0.4	3
26	COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.	6.6	177
27	SARS-COV-2, can you be over it?. <i>World Allergy Organization Journal</i> , 2021, 14, 100514.	1.6	6
28	Suspected Recurrent SARS-CoV-2 Infections Among Residents of a Skilled Nursing Facility During a Second COVID-19 Outbreak – Kentucky, July–November 2020. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 273-277.	9.0	24
29	Persistent viral RNA shedding in COVID-19: Caution, not fear. <i>EBioMedicine</i> , 2021, 64, 103234.	2.7	15
30	Noncompliance With Safety Guidelines as a Free-Riding Strategy: An Evolutionary Game-Theoretic Approach to Cooperation During the COVID-19 Pandemic. <i>Frontiers in Psychology</i> , 2021, 12, 646892.	1.1	48
33	Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases. <i>Viruses</i> , 2021, 13, 512.	1.5	24
34	The Impact of Increasing Disease Prevalence, False Omissions, and Diagnostic Uncertainty on Coronavirus Disease 2019 (COVID-19) Test Performance. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 797-813.	1.2	14
35	Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1713-1719.	1.3	24
36	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.4	38
37	Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG lateral flow assay. <i>PLoS ONE</i> , 2021, 16, e0247797.	1.1	20
38	Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. <i>Nature Immunology</i> , 2021, 22, 620-626.	7.0	320
41	A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 41.	0.9	9
42	The first 12 months of COVID-19: a timeline of immunological insights. <i>Nature Reviews Immunology</i> , 2021, 21, 245-256.	10.6	325

#	ARTICLE	IF	CITATIONS
44	Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLoS ONE, 2021, 16, e0248946.	1.1	71
46	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet, The, 2021, 397, 1459-1469.	6.3	557
47	Incorporating Social Determinants of Health into Modelling of COVID-19 and other Infectious Diseases: A Baseline Socio-economic Compartmental Model. Social Science and Medicine, 2021, 274, 113794.	1.8	31
49	COVID-19 Reinfection in a Patient Receiving Immunosuppressive Treatment for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1091-1092.	2.9	9
50	HOW COVID-19 PATIENT NARRATIVES CONCERNING REINFECTION MIRROR THEIR MENTAL HEALTH: A CASE SERIES. Psychiatria Danubina, 2021, 33, 114-119.	0.2	5
51	The COVID-19 Vaccine in Clinical Trials: Where Are We Now?. Infectious Diseases & Immunity, 2021, 1, 43-51.	0.2	4
52	Pandemic analysis of infection and death correlated with genomic open reading frame 10 mutation in severe acute respiratory syndrome coronavirus 2 victims. Journal of the Chinese Medical Association, 2021, 84, 478-484.	0.6	12
53	Reinfection of SARS-CoV-2 – analysis of 23 cases from the literature. Infectious Diseases, 2021, 53, 1-7.	1.4	12
54	Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection. Lancet Infectious Diseases, The, 2021, 21, 598-599.	4.6	1
55	Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study. Clinical Infectious Diseases, 2022, 74, 622-629.	2.9	61
56	SARS-CoV-2 reinfection: Two cases from Ethiopia. , 0, 2, 114-116.		0
58	Analysis of the potential impact of durability, timing, and transmission blocking of COVID-19 vaccine on morbidity and mortality. Eclinicalmedicine, 2021, 35, 100863.	3.2	35
59	Evidence for immunity to SARS-CoV-2 from epidemiological data series. F1000Research, 0, 10, 50.	0.8	0
60	SARS-CoV-2 Reinfection among Healthcare Workers in Mexico: Case Report and Literature Review. Medicina (Lithuania), 2021, 57, 442.	0.8	10
61	Prolonged viral shedding and antibody persistence in patients with COVID-19. Microbes and Infection, 2021, 23, 104810.	1.0	23
62	Dynamics of SARS-CoV-2 with waning immunity in the UK population. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200274.	1.8	31
63	Modeling COVID-19 with Uncertainty in Granada, Spain. Intra-Hospitalary Circuit and Expectations over the Next Months. Mathematics, 2021, 9, 1132.	1.1	2
64	Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. JAMA Internal Medicine, 2021, 181, 672.	2.6	236

#	ARTICLE	IF	CITATIONS
65	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021, 2021, CD013600.	1.5	109
66	Re-Infection by SARS-Cov-2 with in 5 Months: A Case Report. <i>Biomedical and Pharmacology Journal</i> , 2021, 14, 577-581.	0.2	0
67	Coronavirus new variants: the mutations cause and the effect on the treatment and vaccination. <i>Baghdad Journal of Biochemistry and Applied Biological Sciences</i> , 2021, 2, 71-79.	0.4	9
68	Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2 Seropositive Individuals. <i>Clinical Infectious Diseases</i> , 2022, 74, 893-896.	2.9	5
69	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <i>Advanced Science</i> , 2021, 8, e2100985.	5.6	16
70	Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 670298.	1.8	40
71	Persistent SARS-CoV-2 positivity. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e328-e329.	0.1	7
72	From Isolation to Containment: Perceived Fear of Infectivity and Protective Behavioral Changes during the COVID-19 Vaccination Campaign. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6503.	1.2	14
73	Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. <i>Kidney International</i> , 2021, 99, 1470-1477.	2.6	58
74	Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e362-e370.	2.0	60
75	Mathematical modelling of the second wave of COVID-19 infections using deterministic and stochastic SIRD models. <i>Nonlinear Dynamics</i> , 2021, 106, 1359-1373.	2.7	8
76	Reinfection or relapse of COVID-19 in health care workers; case series of 2 patients from Pakistan. <i>New Microbes and New Infections</i> , 2021, 42, 100896.	0.8	2
77	Recurrent COVID-19 infection in a health care worker: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 363.	0.4	4
78	COVID-19: a confirmed case of reinfection in a nurse. <i>BMJ Case Reports</i> , 2021, 14, e244507.	0.2	6
79	Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0253977.	1.1	35
80	A clinical case of the novel coronavirus (COVID-19) reinfection in a health care worker. <i>Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR</i> , 2021, 27, 195-200.	0.1	0
81	Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2. <i>Viral Immunology</i> , 2021, 34, 504-509.	0.6	5
82	Vaccine Innovation for Pandemic Preparedness: Patent Landscape, Global Sustainability, and Circular Bioeconomy in Post-COVID-19 era. <i>Circular Economy and Sustainability</i> , 2021, 1, 1439-1461.	3.3	8

#	ARTICLE	IF	CITATIONS
83	Modeling the COVID-19 pandemic: a primer and overview of mathematical epidemiology. <i>SeMA Journal</i> , 2022, 79, 225-251.	1.0	17
84	Vaccination certificates, immunity passports, and test-based travel licences: Ethical, legal, and public health issues. <i>Travel Medicine and Infectious Disease</i> , 2021, 42, 102079.	1.5	3
85	Recurrent and persistent infection with SARS-CoV-2 – epidemiological data and case reports from Western Sweden, 2020. <i>Infectious Diseases</i> , 2021, 53, 900-907.	1.4	13
86	Distinguishing repeated polymerase chain reaction positivity from reinfections in COVID-19. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 742-749.	1.5	1
87	Severe acute respiratory syndrome coronavirus 2 reinfection in a coronavirus disease 2019 recovered young adult: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 382.	0.4	3
90	COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection. <i>BMC Infectious Diseases</i> , 2021, 21, 710.	1.3	118
93	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0255335.	1.1	48
94	COVID-19 Reinfection in a Young Medical Doctor: A Case Report. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 712-715.	0.1	0
95	COVID-19 Testing and the Impact of the Pandemic on the Miami Adult Studies on HIV Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1016-1023.	0.9	21
96	COVID-19 Research: Lessons from Non-Human Primate Models. <i>Vaccines</i> , 2021, 9, 886.	2.1	15
99	Containing epidemics in a local cluster via antidote distribution and partial quarantine. <i>Physical Review E</i> , 2021, 104, 034307.	0.8	0
100	Vaccination passports: Challenges for a future of air transportation. <i>Transport Policy</i> , 2021, 110, 394-401.	3.4	30
101	A review of mathematical model-based scenario analysis and interventions for COVID-19. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 209, 106301.	2.6	37
102	Complexities in Case Definition of SARS-CoV-2 Reinfection: Clinical Evidence and Implications in COVID-19 Surveillance and Diagnosis. <i>Pathogens</i> , 2021, 10, 1262.	1.2	0
103	Airborne infection risks of SARS-CoV-2 in U.S. schools and impacts of different intervention strategies. <i>Sustainable Cities and Society</i> , 2021, 74, 103188.	5.1	23
105	COVID-19 vaccination drive in India – Beginning of the end. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 2726.	0.3	0
106	Why decoding the immune response to COVID matters for vaccines. <i>Nature</i> , 2020, 586, 473-474.	13.7	4
112	A case of COVID-19 reinfection in the UK. <i>Clinical Medicine</i> , 2021, 21, e52-e53.	0.8	52

#	ARTICLE	IF	CITATIONS
113	Virtual screening of functional foods and dissecting their roles in modulating gene functions to support post COVID-19 complications. <i>Journal of Food Biochemistry</i> , 2021, 45, e13961.	1.2	11
114	Hyperimmune immunoglobulin for people with COVID-19. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
115	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. <i>Interface Focus</i> , 2021, 11, 20210008.	1.5	24
117	Nationwide assessment of energy costs and policies to limit airborne infection risks in U.S. schools. <i>Journal of Building Engineering</i> , 2022, 45, 103533.	1.6	1
120	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2020, 6, 41-80.	0.1	0
121	Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World. <i>Infectious Diseases &amp; Immunity</i> , 2022, 2, 29-33.	0.2	3
127	COVID-19 vaccinations: The unknowns, challenges, and hopes. <i>Journal of Medical Virology</i> , 2022, 94, 1336-1349.	2.5	75
128	Evaluation of the United States COVID-19 vaccine allocation strategy. <i>PLoS ONE</i> , 2021, 16, e0259700.	1.1	22
129	It took it off most of the time 'cause I felt comfortable' unmasking, trusted others, and lessons learned from a coronavirus disease 2019 reinfection: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 557.	0.4	1
130	SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. <i>Microbial Pathogenesis</i> , 2021, 161, 105296.	1.3	23
131	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. <i>Future Microbiology</i> , 2021, 16, 1415-1451.	1.0	12
132	The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. <i>Annals of Medicine and Surgery</i> , 2021, 72, 103130.	0.5	31
133	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
135	Dynamic data-driven algorithm to predict cumulative COVID-19 infected cases using susceptible-infected-susceptible model. <i>Epidemiologic Methods</i> , 2021, 10, .	0.8	3
136	Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse. , 2021, 25, .		4
137	Regression Models for Understanding COVID-19 Epidemic Dynamics With Incomplete Data. <i>Journal of the American Statistical Association</i> , 2021, 116, 1561-1577.	1.8	16
138	The Different Immune Responses by Age Are due to the Ability of the Fetal Immune System to Secrete Primal Immunoglobulins Responding to Unexperienced Antigens. <i>International Journal of Biological Sciences</i> , 2022, 18, 617-636.	2.6	2
139	The changing dynamics of neutralizing antibody response within 10 months of SARS-CoV-2 infections. <i>Journal of Medical Virology</i> , 2021, , .	2.5	2

#	ARTICLE	IF	CITATIONS
140	The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis. <i>Pathogens and Global Health</i> , 2022, 116, 269-281.	1.0	27
142	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	1.6	79
143	Sexual dimorphism in COVID-19: potential clinical and public health implications. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 221-230.	5.5	78
146	The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine. <i>Annals of Internal Medicine</i> , 2022, 175, 674-681.	2.0	45
148	Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models. <i>Viruses</i> , 2022, 14, 449.	1.5	5
149	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. <i>BMC Immunology</i> , 2022, 23, 7.	0.9	6
150	Multiple COVID-19 Waves and Vaccination Effectiveness in the United States. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2282.	1.2	36
151	Dynamical analysis of the infection status in diverse communities due to COVID-19 using a modified SIR model. <i>Nonlinear Dynamics</i> , 2022, 109, 19-32.	2.7	5
152	COVID-19 reinfection in Liberia: Implication for improving disease surveillance. <i>PLoS ONE</i> , 2022, 17, e0265768.	1.1	7
153	Clinical Features and Time to Recovery of Admitted COVID-19 Cases at Dilla University Referral Hospital Treatment Center, South Ethiopia. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 795-806.	1.1	5
154	Reinfection in COVID-19: Do we exaggerate our worries?. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13767.	1.7	11
155	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. <i>Vaccines</i> , 2022, 10, 479.	2.1	9
156	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e545-e551.	2.9	130
157	Modeling Early Phases of COVID-19 Pandemic in Northern Italy and Its Implication for Outbreak Diffusion. <i>Frontiers in Public Health</i> , 2021, 9, 724362.	1.3	2
158	Clinical Presentation and Course of SARS-CoV-2 Infection in Health-Care Personnel Working in Dedicated COVID-19 Hospital During 2 Pandemic Waves in India. <i>Disaster Medicine and Public Health Preparedness</i> , 2021, , 1-6.	0.7	0
159	Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. <i>Chinese Medical Journal</i> , 2022, 135, 145-152.	0.9	35
160	Protective Effect of Melatonin Administration against SARS-CoV-2 Infection: A Systematic Review. <i>Current Issues in Molecular Biology</i> , 2022, 44, 31-45.	1.0	7
162	The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 916-925.	1.5	11



#	ARTICLE	IF	CITATIONS
164	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
166	Modelling how face masks and symptoms-based quarantine synergistically and cost-effectively reduce SARS-CoV-2 transmission in Bangladesh. <i>Epidemics</i> , 2022, 40, 100592.	1.5	4
167	Epidemiological and clinical characteristics of SARS-CoV-2 reinfections in a Spanish region. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211085.	0.7	2
168	The potential of developing a protective peptide-based vaccines against SARS-CoV-2. <i>Drug Development Research</i> , 0, , .	1.4	2
169	Post pandemic fatigue: what are effective strategies?. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
170	Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	6
171	Reinfection, recontamination and revaccination for SARS-CoV-2. <i>World Journal of Methodology</i> , 2022, 12, 258-263.	1.1	0
173	Investigation Of The Dentists' Fear Of Covid And Psychological Status During Covid-19 Pandemic. <i>Anadolu KliniÄYi TÄ±p Bilimleri Dergisi</i> , 0, , .	0.1	0
174	Analysis of multi-strain infection of vaccinated and recovered population through epidemic model: Application to COVID-19. <i>PLoS ONE</i> , 2022, 17, e0271446.	1.1	2
175	Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition. <i>Npj Digital Medicine</i> , 2022, 5, .	5.7	30
177	Laboratory Findings in Different Disease Status of COVID-19 Admitted Patients at Dilla University Referral Hospital Treatment Center, South Ethiopia. <i>Infection and Drug Resistance</i> , 0, Volume 15, 4307-4320.	1.1	1
178	COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies. <i>Medical Hypotheses</i> , 2022, 167, 110943.	0.8	1
179	Association of Results of Four Lateral Flow Antibody Tests with Subsequent SARS-CoV-2 Infection. <i>Microbiology Spectrum</i> , 0, , .	1.2	2
180	SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria. <i>PLoS ONE</i> , 2022, 17, e0274509.	1.1	8
181	Activity-driven network modeling and control of the spread of two concurrent epidemic strains. <i>Applied Network Science</i> , 2022, 7, .	0.8	2
182	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	0.4	4
184	SARS-CoV-2 infections in certain groups: A review from COVID-19 study cases. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
185	Hyperimmune immunoglobulin for people with COVID-19. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	5

#	ARTICLE	IF	CITATIONS
186	Convalescent plasma for people with COVID-19: a living systematic review. The Cochrane Library, 2023, .	1.5	10
187	Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents. Journal of Pediatrics, 2023, 257, 113371.	0.9	4
188	Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation. Lancet Microbe, The, 2023, 4, e495-e505.	3.4	3
200	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0
201	Trade-offs and political economy during pandemics. , 2024, , 157-199.		0